480 related articles for article (PubMed ID: 12086332)
1. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Motawi TK; El-Maraghy SA; Senousy MA
J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
[TBL] [Abstract][Full Text] [Related]
3. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
Volpini RA; da Silva CG; Costa RS; Coimbra TM
Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643
[TBL] [Abstract][Full Text] [Related]
4. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
[TBL] [Abstract][Full Text] [Related]
5. Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats.
Xu XX; Zhang W; Zhang P; Qi XM; Wu YG; Shen JJ
Phytomedicine; 2013 Jul; 20(10):820-7. PubMed ID: 23664882
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
[TBL] [Abstract][Full Text] [Related]
8. [Effect of selective cyclooxygenase -2 inhibitor on the renal lesion of streptozotocin-induced diabetic rats and its possible mechanism].
Zuo Y; Gu Y; Ma J; Lin S
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):239-43. PubMed ID: 11953170
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Kelly DJ; Cox AJ; Tolcos M; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Kidney Int; 2002 Jan; 61(1):31-9. PubMed ID: 11786082
[TBL] [Abstract][Full Text] [Related]
10. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
[TBL] [Abstract][Full Text] [Related]
11. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
12. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501
[TBL] [Abstract][Full Text] [Related]
14. [Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Miao Y; Zhang W; Zhong M; Ma X; Qi TG; Sun H
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):366-70. PubMed ID: 17456374
[TBL] [Abstract][Full Text] [Related]
15. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
16. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats.
Hill C; Logan A; Smith C; Grønbaek H; Flyvbjerg A
Diabetologia; 2001 Apr; 44(4):495-500. PubMed ID: 11357481
[TBL] [Abstract][Full Text] [Related]
18. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
20. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Moriyama T; Oka K; Ueda H; Imai E
Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
